Tango Therapeutics, Inc.
- TNGX
- NASDAQ
- Biotechnology
- Oncology Drug Development
- Synthetic Lethality (PRMT5)
$23.53
Today +6.76%Quote Oct 19, 2026, 08:00 PM UTC
+8.18%over the last month
Max drawdown −14.5%From 1-month high −7.8%3 months −18.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Tango Therapeutics
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5).
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
137
Market value
$3.97B
Quote Oct 19
Floor
$22.68
3.6% below price
Resistance
$23.83
1.3% above price
Price vs analyst targets
13 analysts
Lowest target
$24.00Highest target
$69.00
$24.00Highest target
$69.00
- Price $23.53
- Average target $45.91
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 95% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about TNGXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free